Categories
Business

Stocks climb more than 2% as investors get back to buying

 

In this photo provided by the New York Stock Exchange, traders work on the floor, Monday, March 1, 2021. Stocks are rising across the board on Wall Street as traders welcomed a move lower in long-term interest rates in the bond market. Investors were also watching Washington as a big economic stimulus bill moved to the Senate. (Courtney Crow/New York Stock Exchange via AP)

 

Stocks are rising across the board on Wall Street as traders welcomed a move lower in long-term interest rates in the bond market. Investors were also watching Washington as a big economic stimulus bill moved to the Senate.

 

The S&P 500 added 2.3% as of 12:25 p.m. Eastern. More than 95% of the stocks in the index were higher, led by energy and technology companies. The Dow Jones Industrial Average was up 642 points, or 2.1%, to 31,574 and the Nasdaq Composite rose 2.5%.

 

Much of the focus on Wall Street is on the bond market.

 

The yield on the 10-year Treasury note fell to 1.43% after going as high as 1.5% last week, the highest level in more than a year. Higher interest rates can slow the economy and discourage borrowing.

Bond yields, which influence interest ratest on mortgages and many other kinds of loans, have been steadily climbing much of the year, as investors have bet that vaccination efforts and more government stimulus will lead to strong economic growth this year. However, along with strong economic growth comes concerns of inflation.

 

A handful high-level officials with the Federal Reserve will make speeches this week, which will give investors additional information on how concerned the nation’s central bank is about the economy and inflation. Lael Brainard, an advocate for looser monetary policies, will give a monetary policy speech on Tuesday and Fed Chair Jerome Powell will give a speech on Thursday.

 

The House of Representatives approved Biden’s $1.9 trillion pandemic relief bill on Friday and it now goes to the Senate for approval. The bill infuses cash across the struggling economy to individuals, businesses, schools, states and cities battered by COVID-19.

 

The stimulus bill would include yet another round of one-time payments to most Americans, including an expansion of other refundable tax credits like the child tax credit, and additional aid to state and local governments to combat the pandemic.

 

Johnson & Johnson rose 1.5% after the Food and Drug Administration gave approval for the company’s own coronavirus vaccine, one that does not require extensive refrigeration like the ones made by Moderna and Pfizer.

 

Energy companies made some of the biggest gains. Exxon Mobil rose 5% and Occidental Petroleum rose 4.9%. Industrial companies, including airlines beaten down by the virus pandemic, also helped boost the broader market. United Airlines rose 3.4%.

 

Investors will get several big economic reports this week, including February’s jobs report on Friday. On Monday a report on manufacturing came in better than expectations, and new orders also came in better than expected.

 

— Associated Press

Categories
Healthcare

LianBio announces $310 million crossover financing

Supported by a strong U.S. and Chinese investor syndicate including Perceptive Advisors, RA Capital, Venrock Healthcare Capital Partners and CMG-SDIC Capital

Proceeds will fund advancement of the Company’s global innovation mining platform and diversified portfolio of product candidates

SHANGHAI & PRINCETON, N.J.–(BUSINESS WIRE)–LianBio, a Chinese company focused on bringing paradigm-shifting medicines to patients in China and major Asian markets, today announced it has raised $310 million in an oversubscribed crossover financing, following its founding and initial financing provided by Perceptive Advisors.

The financing was co-led by U.S. investors RA Capital and Venrock Healthcare Capital Partners and Chinese investor CMG-SDIC Capital. Other leading specialist investors in the round included: funds and accounts managed by BlackRock, Casdin Capital, Farallon, Logos Capital, Perceptive Advisors, Pfizer Inc., Sphera Healthcare, funds and accounts advised by T. Rowe Price Associates, Inc., Tybourne Capital Management, Vida Ventures, Viking Global Investors and Wellington Management.

We are excited to partner with this world class group of investors who share our vision of accelerating broad access to transformative medicines for patients in China and other major Asian markets. Building on the success and momentum of the Company’s recent launch, this financing provides additional support for LianBio’s efforts to contribute to China’s dynamic life sciences landscape by addressing significant unmet medical needs in the region,” said Konstantin Poukalov, Managing Director, Perceptive Advisors and Executive Chairman of LianBio. “We are proud of the management team who is rapidly realizing our vision and has proven that partnership, passion and commitment can help spur the delivery of innovative therapies to the fast-growing biopharma marketplace in China.”

With the Company’s global innovation mining platform validated by an impressive syndicate of investors, LianBio is poised to advance its business model in China and major Asian markets.

Jefferies LLC acted as exclusive placement agent for the financing.

About LianBio

LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics. For more information, please visit lianbio.com.

Contacts

Investor Contact:
Thomas Hoffmann

Solebury Trout

646-378-2931

thoffmann@soleburytrout.com

Media Contact:
Hannah Gendel

Solebury Trout

646-378-2943

hgendel@soleburytrout.com

Categories
Business

KODAK ALERT: Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed against Eastman Kodak Company and encourages investors with losses in excess of $150,000 to contact the firm

NEW YORK–(BUSINESS WIRE)–#EastmanKodakCompany–Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of investors that purchased Eastman Kodak Company (NYSE: KODK) common stock between July 27, 2020 and August 7, 2020 (the “Class Period”). Investors have until October 13, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

The securities class action concerns several matters, including the suspicious timing of insider trading activity in connection with Kodak’s July 28, 2020 announcement that it had reached an agreement with the U.S. government to receive a $765 million loan to produce pharmaceutical ingredients.

As news of the deal broke, Kodak, which had been trading under $2 per share, skyrocketed, and within two days, the stock was trading around $60 per share, with 284 million shares changing hands. Just prior to the announcement of the loan, insiders purchased or were granted over 2 million shares of Kodak stock.

More specifically, the day before the deal was announced, the company granted CEO James Continenza options for 1.75 million shares, just under 29% of which vested immediately. As a result of the suspicious timing of the announcement, lawmakers have asked federal regulators to investigate securities transactions made by the company and its executives around the time Kodak learned it could receive the government loan, and the SEC has announced an investigation. On August 7, 2020, the U.S. International Development Finance Corporation said it was holding up the payout of the loan as regulators look into insider trading activity.

On this News the Company’s stock price declined $4.15, or 28%, from $14.88 per share on August 7, 2020, to $10.73 per share on August 10, 2020.

The complaint, filed on August 13, 2020, alleges that during the Class Period defendants engaged in a scheme to deceive the market and a course of conduct that artificially inflated the prices of Kodak’s securities and operated as a fraud or deceit on Class Period purchasers of Kodak’s securities by failing to disclose to investors that the company’s financial results were materially misleading and misrepresented material information. When defendants’ misrepresentations and fraudulent conduct were disclosed and became apparent to the market, the prices of Kodak’s securities fell precipitously as the prior inflation came out of the Company’s stock price.

If you purchased Kodak common stock during the Class Period and suffered a loss in excess of $150,000, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Bragar Eagel & Squire, P.C.

Melissa Fortunato, Esq.

Marion Passmore, Esq.

(212) 355-4648

investigations@bespc.com
www.bespc.com

Categories
Business

Hudson announces earnings call to discuss second quarter 2020 results

EAST RUTHERFORD, N.J.–(BUSINESS WIRE)–Hudson (NYSE: HUD) (“Hudson” or the “Company”), a North American travel experience leader with more than 1,000 stores in airports, commuter hubs, landmarks and tourist destinations, today announced that it will release its results for the second quarter ended June 30, 2020 before the market opens on Monday, August 3, 2020. The Company will hold a conference call and webcast on Monday, August 3, 2020 at 10:00 am ET to discuss its results.

We encourage participants to pre-register for the conference call using the following link: http://dpregister.com/10145976

Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

A live, listen-only webcast of the call will be available at the following link: https://services.choruscall.com/links/hson200803.html

Those without internet access or unable to pre-register may dial in by calling:

PARTICIPANT DIAL IN (TOLL FREE): 1-833-255-2832

PARTICIPANT INTERNATIONAL DIAL IN: 1-412-902-6725

The webcast will be archived for three months on our investor relations website at https://investors.hudsongroup.com.

About Hudson

Hudson, a Dufry Company, is a travel experience company turning the world of travel into a world of opportunity by being the Traveler’s Best Friend in more than 1,000 stores in airport, commuter hub, landmark, and tourist locations. Our team members care for travelers as friends at our travel convenience, specialty retail, duty free and food and beverage destinations. At the intersection of travel and retail, we partner with landlords and vendors, and take innovative, commercial approaches to deliver exceptional value. To learn more about how we can make your location a travel destination, please visit us at www.hudsongroup.com.

Contacts

Investors/Media
Cindi Buckwalter

VP of Investor Relations & Corporate Communications

investorrelations@hudsongroup.com
communications@hudsongroup.com